The labs of SynthImmune PIs Lukas Bunse, Katharina Lindner, and Michael Platten have published a paper in the journal Nature Cancer entitled “IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial”.
In it, the authors report on the clinical and immunological long-term follow-up of a multicenter, first-in-human phase 1 trial that met its prespecified primary endpoints by demonstrating safety and immunogenicity of an IDH1-R132H peptide vaccine (IDH1-vac) integrated into standard of care in 33 participants. The favorable long-term outcome of the NOA16 cohort supports investigating IDH1-vac in persons with newly diagnosed grade 3 and 4 IDH-mutant astrocytomas in a randomized phase 2 trial.
Read the full story here.
